Technical Analysis for RDUS - Radius Health, Inc.

Grade Last Price % Change Price Change
grade C 22.165 -0.96% -0.22
RDUS closed down 0.67 percent on Thursday, July 18, 2019, on 60 percent of normal volume. It was able to find support at its 50 day moving average. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Down
See historical RDUS trend table...

Date Alert Name Type % Chg
50 DMA Support Bullish -0.96%
Lower Bollinger Band Walk Weakness -0.96%
Oversold Stochastic Weakness -0.96%
MACD Bearish Centerline Cross Bearish -1.62%
Bullish Engulfing Bullish -1.62%
Crossed Above 50 DMA Bullish -1.62%
Stochastic Buy Signal Bullish -1.62%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -1.62%
Outside Day Range Expansion -1.62%
Lower Bollinger Band Touch Weakness -1.62%

Older signals for RDUS ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Radius Health, Inc., a biopharmaceutical company, focuses on developing novel therapeutics for patients with osteoporosis and other serious endocrine-mediated diseases in the United States. Its lead product includes abaloparatide (BA058), a novel synthetic peptide analog of parathyroid hormone-related protein, which is in Phase III clinical development for the treatment of osteoporosis. The company is also developing RAD1901, a selective estrogen receptor down-regulator/degrader for the treatment of breast cancer brain metastases, and vasomotor symptoms; and RAD140, a nonsteroidal selective androgen receptor modulator, which is in preclinical development stage for the treatment of weight loss due to cancer cachexia, muscle frailty and osteoporosis, and breast cancer. It has collaborations and license agreements with Nordic Bioscience Clinical Development VII A/S; 3M; Ipsen Pharma SAS; Eisai; Lonza Group Ltd.; and Charles River Laboratories, Inc. The company was founded in 2003 and is headquartered in Cambridge, Massachusetts.
Biopharmaceutical Cancer Drugs Breast Cancer Endocrine System Hormones Osteoporosis Amines Treatment Of Breast Cancer Antiestrogens Eisai Selective Estrogen Receptor Modulators
Is RDUS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 0 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 28.84
52 Week Low 12.81
Average Volume 495,563
200-Day Moving Average 19.2697
50-Day Moving Average 22.3372
20-Day Moving Average 23.426
10-Day Moving Average 22.959
Average True Range 0.9438
ADX 14.84
+DI 22.3594
-DI 20.8623
Chandelier Exit (Long, 3 ATRs ) 22.5636
Chandelier Exit (Short, 3 ATRs ) 24.4814
Upper Bollinger Band 25.2276
Lower Bollinger Band 21.6244
Percent B (%b) 0.21
BandWidth 15.3812
MACD Line -0.0547
MACD Signal Line 0.2281
MACD Histogram -0.2828
Fundamentals Value
Market Cap 970.95 Million
Num Shares 43.4 Million
EPS -5.19
Price-to-Earnings (P/E) Ratio -4.31
Price-to-Sales 1353.51
Price-to-Book 6.40
PEG Ratio -0.13
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 23.72
Resistance 3 (R3) 23.76 23.35 23.49
Resistance 2 (R2) 23.35 23.01 23.33 23.42
Resistance 1 (R1) 22.87 22.80 22.67 22.83 23.34
Pivot Point 22.46 22.46 22.36 22.44 22.46
Support 1 (S1) 21.98 22.12 21.78 21.94 21.42
Support 2 (S2) 21.57 21.91 21.55 21.34
Support 3 (S3) 21.09 21.57 21.27
Support 4 (S4) 21.05